The interpretation of the results obtained from immunomonitoring of clinical trials is a diYcult task due to the variety of methods and protocols available to detect vaccine-speciWc T-cell responses. This heterogeneity as well as the lack of standards has led to signiWcant scepticism towards published results. In February 2005, a working group was therefore founded under the aegis of the Association for Immunotherapy of Cancer ("CIMT") in order to compare techniques and protocols applied for the enumeration of antigen-speciWc T-cell responses. Here we present the results from two consecutive phases of an international inter-laboratory testing project referred to as the "CIMT monitoring panel". A total of 13 centers from six European countries participated in the study in which pretested PBMC samples, synthetic peptides and PE-conjugated HLA-tetramers were prepared centrally and distributed to participants. All were asked to determine the number of antigen-speciWc T-cells in each sample using tetramer staining and one functional assay. The results of the Wrst testing round revealed that the total number of cells analyzed was the most important determinant for the sensitive detection of antigen-speciWc CD8 + T-cells by tetramer staining. Analysis by ELISPOT was inXuenced by a combination of cell number and a resting phase after thawing of peripheral blood mononuclear cells. Therefore, the experiments were repeated in a second phase but now the participants were asked to change their protocols according to the new guidelines distilled from the results of the Wrst phase. 
Introduction
In the last two decades, more than 200 clinical trials of diVerent anti-tumor vaccines aiming to induce tumor-speciWc immunity in cancer patients have been described [1] . Most of these trials primarily assessed safety and immunogenicity while reporting partial or complete clinical responses in a minority of patients [2, 3] . Despite the fact that the low fraction of clinical responders still precludes the establishment of a direct correlation between clinical eYcacy and T-cell reactivity, it has become clear from animal models and clinical observations that naturally-occurring or vaccine-induced CD8 + or CD4 + T-cells play an important role in the control and regression of tumors [4] [5] [6] [7] [8] [9] . Therefore, the number of subjects that mount a vaccineinduced T-cell response as well as the strength of a detected T-cell response represent important surrogate markers for vaccine eYcacy. The enzyme-linked immunospot (ELI-SPOT) assay [10, 11] , staining with HLA-peptide multimers [12] and intracellular cytokine staining (ICS) [13, 14] are technologies used commonly for the monitoring of antigen-speciWc immune responses. For these three assays, a huge variety of diVerent protocols are available worldwide. This heterogeneity, together with the fact that the sensitivity of the individual protocols can vary signiWcantly, makes a comparison of the results obtained in diVerent trials a diYcult task. Moreover, an increasing number of new technologies are constantly being introduced to the Weld, which makes interpretations even more complex [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
Current data and opinion support the use of a functional assay like the ELISPOT or ICS in combination with a phenotyping assay like HLA-multimers [26, 27] , but recognized international standards for all these methodologies are still lacking.
The main aim of the "CIMT monitoring panel" is to harmonize and optimize the monitoring of antigen-speciWc T-cells among the participating laboratories, based on objective rationales with respect to the testing procedure, the analysis and the interpretation of results. Important requirements for an immunological test are sensitivity, applicability to large amounts of clinical material and feasibility at reasonable cost. The results generated by the tests should be reproducible and sensitive, independently of the place where they have been performed. After the Wrst meeting of the working group, a series of inter-laboratory testing projects was initiated, in which individual laboratories could compare their performance, express their needs and exchange experience in order to improve their local assays. Here we report the results of the Wrst two phases of the CIMT monitoring panel, with 13 participating centers from six European countries.
Uppsala, Sweden), washed two times in RPMI 1640 (GIBCO BRL, Grand Island, NY, USA) containing 10 mM Hepes buVer, L-arginine (116 mg/ml), L-glutamine (216 mg/ ml), penicillin (10 IU/ml), streptomycin (100 mg/ml) and 10% FCS (GIBCO BRL), counted and frozen at 10 to 20 £ 10 6 cells per cryovial in 1 ml of FCS 90% + DMSO 10% at ¡80°C in freezing-boxes Wlled with iso-propanol. After 20 h, all cryovials were transferred to liquid nitrogen and stored until distribution to the participating laboratories.
Pre-screening and selection of the PBMC donors for inXuenza-and CMV-T-cell reactivities were performed by a central lab using the IFN ELISPOT assay following a local protocol as described previously [38] . Five donors were selected for the Wrst phase of the panel and eight for the second phase. One HLA-A*0201-negative donor was included in each phase (negative control), all other samples were HLA-A*0201-positive.
Synthetic peptides and HLA-tetramers
Peptides were synthesized using standard Fmoc chemistry, dissolved at 10 mg/ml in DMSO, aliquotted and stored at ¡80°C. The purity was checked by reverse-phase HPLC and was found to be >80%. Two known HLA-A*0201 Tcell epitopes were used: inXuenza MP 58-66 GILGFVFTL and HCMV pp65 495-503 NLVPMVATV (http://www. syfpeithi.de). Biotinylated recombinant HLA-A*0201 monomers folded with the inXuenza MP 58-66 or the HMCV pp65 peptides were produced essentially as described, puriWed by gel Wltration and stored as aliquots at ¡80°C [12] . Fluorescent multimers were obtained by incubation with streptavidin-PE (Molecular Probes, Leiden, The Netherlands), then frozen as aliquots after addition of 0.5% BSA and 16% glycerol. HLA-concentrations of inXuenza-tetramer and HCMV-tetramers were 700 and 350 g/ ml, respectively. Both tetramers were checked by HPLC and/or validated by staining of a speciWc CD8 + T-cell line (InXuenza) or PBMC from HLA-A2-negative and HLA-A2-positive CMV seronegative donors (CMV). Such tetramers are stable at 4°C for at least 1 month (personal observation) and participants were asked to perform all tests within this time period.
Participating centers
Twelve centers from Wve European countries participated in the Wrst phase of the monitoring panel. As one of the investigators moved to another institution during the study a 13th center from a 6th European country was added to the group in the second phase of the panel. Participation in the panel was open to all interested laboratories with a focus on T-cell monitoring, independently of membership in the Association for Immunotherapy of Cancer.
Reagent distribution and assay guidelines
Coded PBMC samples, synthetic peptides and HLA-A*0201 tetramers were shipped on dry ice to the participants. Additionally, guidelines for the two T-cell assays were distributed for each phase:
Phase I/2005. A protocol for tetramer staining was included. BrieXy, 1 £ 10 6 PBMC per test were transferred directly after thawing into one well of a 96 well u-bottom plate and washed in FACS buVer consisting of PBS, 2% FCS, 2 mM EDTA, 0.02% azide. Incubation with 5 g/ml HLA-tetramer was then performed in FACS buVer with 50% FCS for 30 min at room temperature in the dark. After one wash in FACS buVer, mAb for T-cell staining were added for 20 min at 4°C. Finally, cells were washed twice before Wxing in FACS buVer containing 1% formaldehyde solution. Three mAb combinations were proposed, CD8 alone, CD3 plus CD8, or CD4 plus CD8. Each lab could choose here the antibody clones, Xuorescent dye and concentrations used. Stainings were performed in duplicate.
For the functional assays, synthetic peptides were diluted at 1 mg/ml in PBS as a stock solution. Concentrations in further tests were 1-10 g/ml, left to the choice of the participants. There were no recommendation which functional test should be performed, so that each group could choose the test either routinely used, or to be implemented for its own needs. In this Wrst phase, 11/12 laboratories chose the IFN ELISPOT assay, one lab (Z10) a FACS-based intracellular IFN staining and one lab performed both assays (Z7). Spot counting was performed locally.
Phase II/2006 . Following the results obtained in the Wrst testing phase, requirements were introduced and participants were asked to apply exactly these new criteria (two for the tetramer staining, and four for the ELISPOT, see "Results" section). The assay guidelines were modiWed accordingly. However, in order to reduce the variability in the FACS analysis of the 13 laboratories, a Wgure showing exemplary dot-plots, settings of gates and quadrants, and statistical analysis was provided. All laboratories were now required to perform an IFN ELISPOT as the functional test, with a Wxed peptide concentration of 1 g/ml. Participants were encouraged to use a distributed model protocol but were allowed to use their local protocol, provided that they applied the four new requirements introduced in the second phase.
Collection and analysis of results
After performing the required tests in each phase, participants returned a completed report form containing all relevant information. Number of cells recovered after thawing was included to assess viability after transport. For the tetramer staining experiments, mAb clone, manufacturer, amount, cytometer type and number of lymphocytes and/or CD8 + cells analyzed were noted. Results were expressed as percentage of tetramer-positive cells among CD8 + , CD3 + CD8 +, or CD4 ¡ lymphocytes, depending on which mAb combination was used for the staining. Additionally, FACS dot-plots containing all gates, quadrants and deduced statistical analysis were collected. For the functional test, medium and thawing procedure (e.g. addition of DNAse, of a resting phase, etc.) had to be described, as well as the number of cells per test, the antibodies used (clone, manufacturer, concentration), the Wnal peptide concentration and the incubation times. For the ELISPOT assay, the type of plate, the enzymatic visualization system and the spot reader were also noted. Absolute spot numbers were given by each participant, and Wlter plates were kept for possible second analysis.
All results from both phases were collected and centrally analyzed. For the tetramer stainings, the number of lymphocytes, number of CD8 + T-cells and frequencies of tetramerpositive cells were calculated on the basis of the stainings and statistics provided by the participants. Apart from these calculated frequencies, a "visual evaluation" was necessary (see "Results"). For the ELISPOT, analysis was performed based on the spot numbers reported by the participants, followed by a student t test. Results were accepted as positive reaction only when the numbers of antigen-speciWc spots exceeded the number of spots in the background wells by atleast a factor two. The coeYcients of variation (CV) were calculated for all results (CV = SD/mean £ 100) and are shown in supplementary Tables S1a, b.
The raw data from both panel phases will be provided to interested readers upon request.
Results

Phase I/2005 of the interlaboratory testing project-general aspects
Coded PBMC samples from four HLA-A*0201-positive and one HLA-A*0201-negative healthy donor (D1-D5) were included in this Wrst testing phase. The thawing procedure for PBMC samples in the test centers was not standardized and the recovery of viable cells varied greatly between 45 and 102% (mean 73%) in the 12 labs. However, the number of cells recovered was in all cases suYcient to perform the required analyses. When all the data from the tetramer staining and functional tests were combined it became clear that subjects D1 and D5 had responded to the HLA-A*0201 restricted CMV-derived peptide, consistent with their CMV seropositive-status, and that subjects D1, D2, D3, and D5 had responded to inXuenza. In total, each laboratory should in theory have been able to measure six positive (2£ CMV and 4£ inXuenza) responses.
Detection of antigen-speciWc T-cells by tetramer staining and IFN ELISPOT
The protocol required that all PBMC samples should be analyzed by the 12 participants for the presence of HLA-A*0201-restricted CMV-speciWc and inXuenza-speciWc CD8 + T-cells using centrally-prepared tetramers. The indicated frequencies of antigen-speciWc CD8 + cells generally represent the mean of two separate stainings with CD3 Ab/CD8 Ab/ tetramer, except for centers Z1 (CD8/tetramer), Z7 (CD3/ CD4/CD8/tetramer), Z5 and Z10 (one staining CD3/CD8/ tetramer and one staining CD3/CD4/tetramer) and are based on the analysis and dot plots provided by each participant. As illustrated in Fig. 1 , the absolute numbers of tetramer-positive T-cells were inXuenced by the individual decision of where to set the gates and quadrant markers for the analysis. For example, the inclusion of the subset of T lymphocytes expressing CD8 at a low density inXuenced the number of CD8 + and consequently the frequency of tetramer + cells. Moreover, non-speciWc binding of the tetramer (as seen on the CD8-negative subset) also varied between the diVerent laboratories. For these reasons, not only the frequencies, but also the appearance of the tetramer-positive populations was carefully examined. Two parameters were chosen for validation of "positive" results: (1) a clustered, but not diVuse, tetramer binding-population, and (2) strong intensity of tetramer staining, especially marked for the CMV-tetramer-binding population (Fig. 1) . Table 1 shows: (I) the minimum, mean and maximum frequencies of antigen-speciWc CD8 + T-cells, (II) the results obtained from the individual centers Z1-Z12, and (III) the number and percentage of centers that detected a response. The high frequencies of CMV-speciWc CD8 + T-cells in donors D1 and D5 were readily detected by all participants (mean of 1 per 141 CD8 § 113 in D1 and mean of 1 per 80 CD8 § 24 in D5, respectively). For inXuenza-speciWc CD8 + T-cells, the results were more variable. InXuenzatetramer + cells in donor D3 were detected by all participants with a mean frequency of one cell in 1014 CD8 + T-cells § 355. In Donor D5, 11 of 12 laboratories detected a mean of one tetramer binding cell per 1106 CD8 + T-cells § 508. InXuenza-speciWc cells were less numerous in healthy subjects D1 and D2 and were only detected by Wve and eight laboratories, respectively. No false positive reactivity was reported by any of the participants.
Eleven laboratories analyzed the Wve PBMC samples for the presence of HLA-A*0201-restricted CMV-speciWc and inXuenza-speciWc IFN -producing T-cells by ELISPOT assay. Only one group (Z10) used an intracellular cytokine staining as a functional test (data not shown because no comparison with other groups possible). Table 2 shows (I) the minimum, mean and maximum frequencies of antigenspeciWc cells, (II) the results obtained from the individual centers Z1-Z12, and (III) the number and percentage of centers that detected each reactivity. As described in the "Materials and methods", results of spot-forming cells per seeded PBMC were accepted as a positive reaction only when passing statistical testing and when the number of antigen-speciWc spots exceeded the number of spots in the background wells by at least a factor of two. IFN -producing cells reactive against CMV were detected by 10 of the 11 laboratories in donor D1 (mean reactivity was 1 per 1,855 PBMC § 825) but only by 8 of 11 in donor D5 (mean reactivity was 1 per 4,405 PBMC § 3,762). The inXuenza-speciWc T-cells present in subject D3 were detected by six laboratories, while the responses in the healthy subjects with markedly lower numbers of peripheral speciWc shows results for tests with the CMV-tetramer, the lower panel shows results for tests with the inXuenza-tetramer. In all dot-plots, the tetramer staining is displayed on the y-axis and anti-CD8-staining on the xaxis. Number of counted CD8 + T-cells and percentage of tetramer-positive cells among the CD8 subset are indicated T-cells (D1, D2 and D5) were detected by three laboratories only.
Subgroup analysis reveals that the number of CD8 + T-lymphocytes analyzed aVects the sensitivity of the tetramer staining
Although the tetramer stainings were performed with centrally prepared reagents following set guidelines, centers were left free to select several parameters according to their own protocols, and this could have inXuenced the test results (see "Materials and methods"). Most of the participants used monoclonal antibodies speciWc for CD3 and CD8 to co-stain the cells. There were no obvious diVerences in the performance of the centers depending on which antibody clones, antibody combinations or cytometer were used (data not shown).
There was a high degree of variability in the number of CD8 + cells which were analyzed per staining, ranging from only 0.5 £ 10 4 to about 19 £ 10 4 (inter-center variation). In addition, a non-negligible intra-center variation was observed for the number of counted CD8 + . We therefore analyzed each individual staining independently of the center that performed it and focused on the number of CD8 + T-cells that had been counted. For the six diVerent antigen-speciWc populations detectable, a total of 68 tests was performed by the group (see Table 1 ). Overall, antigen-speciWc T-cell reactivities were reported in 82% of the tests (56/68, mean of duplicate stainings). When less than 30,000 CD8 + T-cells were counted, only 70% of all responses were found. In contrast, 89% of all responses were manifest when more than 30,000 CD8 + T-cells were counted (Fig. 2a) . When antigen-speciWc T-cells were present at high frequency, the number of cells counted did not inXuence the result, because CMV-speciWc T-cells from donors D1 and D5 were detected irrespective of the number of CD8 + Tcells in the test. However, for the inXuenza-speciWc cells, positivity was registered in only 75% of all tests performed (36 of 48 tests). Strikingly, we observed a marked diVerence for the results derived from those tests involving less than 30,000 CD8 + T-cells (56% success in detection) as compared to tests performed with more than 30,000 CD8 + T-cells (84%). In conclusion, the ability to detect antigen-speciWc T-cell reactivities by tetramer staining was mainly aVected by the number of CD8 + T-cells stained and analyzed, especially when the antigen-speciWc T-cells were present at low or moderate frequencies. We therefore modiWed our guidelines for the tetramer assay and recommended staining at least 1 £ 10 6 PBMC and analyzing all cells in the tube. In addition, we provided an example of how optimal cell gates and dot-plot quadrants could be selected.
ELISPOT assays are heterogeneous and require standardization
The ELISPOT analyses were performed according to 11 more or less diVerent protocols. The most discernible diVerences that were observed in these protocols concerned (1) the diVerent types of multi-screen plates, (2) the serum origin, (3) the use of duplicates, triplicates or quadruplicates, (4) the use of allogeneic APC, (5) the inclusion of a resting phase after thawing the PBMC, (6) the number of PBMC per well, (7) the type of antibodies used, (8) the type of spot-reader, and the (9) enzyme and substrate for staining of the spots. Each center also used a diVerent plate protocol (distribution of the wells, number of replicates, control tests).
The inXuence of each of these parameters on the number of positive responses was studied by further analysis in which the laboratories were divided into two subgroups. As a result, several criteria were identiWed which could help to improve the sensitivity and comparability of detection.
All data sets (duplicates, triplicates or quadruplicates) were Wrst analyzed by Student t test for unpaired samples ("Materials and methods"). In our panel, one center used quadruplicates, nine centers used triplicates and one center performed the ELISPOT analysis in duplicates. Due to the variety in the replicates, responses measured by duplicate wells failed to pass the Student t test more often as compared to triplicates.
Overall, the 11 centers were able to detect 50% of all possible reactivities in this panel phase (Table 2 ; Fig. 2b) . In a subgroup of three laboratories (Z5, Z6 and Z8), an allogeneic APC population (T2 or K562-A*0201 cells) was added for binding and presentation of the synthetic peptides. The three centers that used allo-APC detected only 28% of all responses, while the other centers detected 58% of all responses.
In Wve laboratories (Z3, Z4, Z7, Z8, and Z9) PBMC were thawed, and then incubated in culture medium at 37°C. After this resting phase of 2-20 h, living cells were washed, counted and seeded into ELISPOT plates. Laboratories using a resting phase detected 73% of the positive reactivities (22 out of 30 potentially positive tests). No signiWcant diVerence in the ability to detect antigen-speciWc T cells was found using shorter or longer resting-times. In contrast, the laboratories that did not use a resting procedure detected only 30% of all positives (Fig. 2b) .
Finally, the number of cells seeded per well diVered considerably between all participants and ranged from 1 to 6 £ 10 5 PBMC. We divided the laboratories arbitrarily into two groups, those using either more than 4 £ 10 5 PBMC (Z4, Z7, Z8, and Z9) or less than 4 £ 10 5 PBMC (Z1, Z2, Z3, Z11 and Z12). The Wrst group detected 71% of all positive samples, whereas the second group was able to detect only 43% of all positives (Fig. 2b) . Centers Z5 and Z6 used a deWned number of separated CD8 + T-cells in the ELI-SPOT and were therefore not included in this subgroup analysis.
None other of the nine depicted protocol variables had any obvious impact on the detection of speciWc T-cells. As a conclusion from these results, four minimum requirements were formulated for the ELISPOT protocol: (1) 
Phase II/2006 of the interlaboratory testing project-general aspects
To formally prove that the requirements formulated for tetramer staining and ELISPOT analysis increase the ability of the participants to detect antigen-speciWc CD8 + T-cells and reduce the inter-center variability, we decided to repeat the analysis in a second phase of the panel, with the same participants (phase II/2006). In this round, all groups were asked to follow our modiWed guidelines for the tetramerand the ELISPOT-assays.
Again, all PBMC samples were prepared and pre-tested in one central lab and peptide antigens and PE-conjugated tetramers were also provided from one source. As one investigator had meanwhile moved to another lab, we added a 13th center to the group. PBMC from seven selected healthy HLA-A*0201-positive donors and 1 HLA-A*0201-negative donor (D3) were required to be analyzed for the presence of HLA-A*0201-restricted CMV-speciWc T cells and for inXuenza-speciWc T-cells. The mean number of recovered cells after thawing was suYcient to perform the tests. When all the data were combined, it became clear that subjects D2, D5 and D8 possessed CMV-speciWc CD8 + T-cell subsets, and D1, D2, D4, D6 and D7 possessed inXuenza-speciWc CD8 + T-cells. Therefore, each laboratory could theoretically have measured eight positives (3£ CMV and 5£ InXuenza) in this second phase.
Analysis of CD8
+ T-cell tetramer binding using the new guidelines
In the second phase, a total of 104 tests were performed to detect the eight possible tetramer reactivities. Following the modiWed guidelines for tetramer staining, the mean number of CD8 + T-cells that were counted in each separate test increased markedly (+36%): a mean of about 49,000 CD8 + cells were analyzed in the phase I (n = 68 tests) and a mean of 67,000 CD8 + T-cells in phase II (n = 104 tests). The number of cells per test ranged from 12,000 to 467,000 CD8 + . In 81% (84 of 104) of the tests >30,000 CD8 + were counted (compared to 66% of all relevant tests in the Wrst phase). Table 3 shows (I) the minimum, mean and maximum frequencies of antigen-speciWc T-cells, (II) the results obtained from the individual centers Z1-Z13, and (III) the number and percentage of centers that detected each T-cell speciWcity. Donors D2, D5 and D8 showed very strong reactivities with the CMV-tetramer, with mean frequencies of 1/45 CD8 + T-cells, 1/37 CD8 + T-cells, and 1/19 CD8 + T-cells, respectively. All 13 laboratories were able to detect + T-cells) which were found by 12, 9 and 9 centers, respectively. Three laboratories also reported inXuenza tetramer-binding CD8 + cells in D5 or D8. According to the results of the other centers as well as from the ELISPOT (see below), these stainings were considered as false positive (not shown). One center (Z13) was not able to detect any of the inXuenza-speciWc CD8 + T-cell reactivities. Finally, no tetramer + cells were described in the HLA-A*0201-negative donor (D3).
Analysis of CD8 + T-cell responses by ELISPOT following the introduction of a set of four rules
In this second phase, all laboratories performed ELISPOT analysis following local protocols, all of which conformed to the newly introduced minimum requirements. Table 4 shows (I) the minimum, mean and maximum frequencies of antigen-speciWc cells, (II) the results obtained from the individual centers Z1-Z13, and (III) the number and percentage of centers that detected the response. High frequency T-cell responses against CMV could readily be detected by all 13 centers in donors D5 and D8 and by 12 of 13 in donor D2. Failure of center Z4 to detect the CMV reactivity in donor D2 was due to a very high background of the medium control. The number of spots representing IFN -producing cells after inXuenza-peptide stimulation was generally lower, and consequently, the inXuenzaspeciWc T-cell responses in subjects D1, D2, D4 and D6 were detected by fewer laboratories (four centers for D1, three centers for D2, two centers for D4 and ten centers for D6). The high numbers of inXuenza-speciWc T-cells present in D7 were detected by all 13 laboratories (Table 4) .
Comparison of the results obtained in both phases
When the mean frequencies of all T-cell responses in both testing rounds were compared, it became clear that there was a diVerence in the distribution of reactivities (Fig. 3) . In the tetramer assay, the mean T-cell frequency of the six possible positives in the Wrst phase was 1 per 2,083 CD8 To allow a comparison of the overall performance in both phases of the panel, we therefore decided to deWne theoretical thresholds for high, moderate and low T-cell responses and then to compare data of the participating laboratories within these groups.
In order to deWne such thresholds for low, medium and high T-cell responses, we Wrst displayed the probability of detecting each of the 14 diVerent reactivities as a value in a coordinate system and inserted a trendline. For both the tetramer assay and the ELISPOT assay, we observed a clear correlation between the frequencies of antigen-speciWc T-cells and the number of participating centers that were able to detect these populations. We then calculated the theoretical frequencies at which 90% (y = 90) and 50% (y = 50) of all participants could detect a given response (Fig. 4a, b ) and used these two thresholds to divide all reactivities into three distinct classes of T-cell responses ("high", "moderate" and "low").
For the tetramer assay, T-cell frequencies exceeding 1 per 1,200 CD8 + T-cells were therefore classiWed as "high", whereas frequencies of less than 1 per 7,650 CD8 + were classiWed as "low" (Fig. 4a) . Following the same rules for the ELISPOT assay, T-cell responses of at least one IFN spot per 2,850 PBMC can be considered as "high" and Tcell responses of less than one spot per 19,000 PBMC as "low" (Fig. 4b) .
With these calculated assay-speciWc thresholds for high, moderate and low T-cell responses, we compared the results obtained in the two phases. For the tetramer assay, the ability to detect high frequency T-cells (>1 per 1,200 CD8 + ) did not diVer in the two phases, and was not inXuenced by the number of CD8 + analyzed, as previously seen for each of the two phases separately (Fig. 5a) . However, for moderate and low T-cell frequencies, we found that they could be successfully detected in only 54% of cases in the Wrst phase but this improved to 77% in the second phase. Moreover, here, the number of cells counted did have an impact on the ability to detect low frequency T-cells. In the Wrst phase, only 14% were detected when less than 30,000 CD8 + were counted, as compared to 71% when more than 30,000 CD8 + T-cells were counted. The same trend was observed in phase II/2006, but in this case 40% of assays with less than 30,000 CD8 + successfully detected the moderate to low T-cell frequencies compared to 83% counting more than 30,000 CD8 + (Fig. 5a ). We then analyzed the capacity of the laboratories to measure either high T-cell responses (>1 per 2,850 PBMC) or low to moderate T-cell responses (<1 per 2,850 PBMC) in the ELISPOT assay. This analysis was performed for two deWned subgroups of participants. The Wrst subgroup included those Wve centers (Z3, Z4, Z7, Z8 and Z9) that already fulWlled three or four of the requirements in the Wrst phase of the panel. These Wve centers did not have to introduce any change or at least no major changes to their protocol for the repetition of the experiments in phase II. The second subgroup included the new center Z13 (led by a colleague that had been in a laboratory that only fulWlled one of four requirements in phase I) and all others that had fulWlled only one or two of the four requirements in the Wrst phase. All laboratories in this second group had to introduce marked changes to their locally established protocols.
Similar to the tetramer analysis, the new requirements were not necessary to detect antigen-speciWc responses among the category of high T-cell frequencies in either the Wrst or second phases (Fig. 5b) . However, applying the set of rules deWned in phase I markedly improved the capacity of centers to detect the low to moderate T-cell responses. The Wrst subgroup detected a total of 68% of the low to moderate reactivities in phase I, whereas the second subgroup detected only 20% (Fig. 5b) . After harmonization of the protocols, both subgroups performed equally well. In addition, the inter-group variability in detecting positive responses was reduced in phase II (percentage of detected responses ranged from 38 to 88% with a mean of 67 § 16%) as compared to phase I (percentage of detected responses ranged from 0 to 100% with a mean of 55 § 33%).
Experience does not equal performance Among the 13 centers that had participated in phase II, tetramer stainings had been performed for 1-8 years. Similarly, the experience in the ELISPOT technology varied between 1 and 10 years. For both techniques, we could not Wnd any correlation between the years of experience and the ability to detect T-cell responses, not even among the subgroups of moderate or low T-cell responses (not shown).
Discussion
Whenever new techniques are introduced to the scientiWc community, they are Wrst only available to a small group of expert laboratories. If these assays are robust and applicable for speciWc research or routine applications, they spread to the international community. In general, the "original" protocol then undergoes several adaptations in order to meet speciWc needs. On the one hand, changes can be beneWcial and result in the improvement of protocols. On the other, this evolutionary process leads to employment of many diVerent protocol variants, limiting comparison of the study results obtained by diVerent laboratories. Thus, standardization approaches should be omitted during the initial development but are absolutely required when assays have become Wrmly established. In recent years, several activities aiming at the harmonization of techniques used to monitor the presence of antigen-speciWc T-cells have been initiated for ELISPOT [28] [29] [30] [31] , tetramer staining [32] and ICS [33] [34] [35] [36] . While these studies showed the feasibility, general applicability and the diversity of performance among participants, they were not designed to either systematically investigate the inXuence of distinct protocol variables nor to test whether changes to these parameters can lead to a global improvement of the group. The CIMT monitoring panel is the Wrst initiative that has now introduced the two-step approach proposing a strategy where technical variables that inXuence the performance of a deWned assay are Wrst systematically identiWed ("Wrst step") followed by a new testing phase where resultant protocol changes are validated under controlled conditions within the same group of investigators ("second step").
As soon as a number of protocol variables that might have inXuenced the sensitivity and the quality of the tests were identiWed in the Wrst phase of our study, it was decided to validate this Wnding in a second phase. Because this two-step approach was not initially foreseen, the second phase was performed with PBMC samples obtained from diVerent donors than those used in the Wrst round. The distribution and the frequencies of detectable T-cell responses directed against the chosen model antigens were diVerent in the Wrst and second group of donors (Fig. 3) precluding a direct comparison of the results obtained in both phases of the panel. To circumvent this problem, two assay-speciWc frequency thresholds were introduced that allowed us to distinguish classes of T-cell responses (low, moderate and high) (Fig. 4a, b) . Clearly, high-frequency Tcell responses were detected irrespective of the protocol used and as such did not allow the identiWcation of factors that exert a strong inXuence on the sensitivity and variability of the protocols used. Relevant parameters could only be detected when the comparison was focused on the detection of T-cells that are present at low to moderate frequencies in PBMC. This Wnding should be taken into account when selecting model antigens for use in monitoring panels [37] , in particular by laboratories that are interested in the detection of peripheral tumor-speciWc T-cells, which are often present at low frequencies, even after vaccination.
Although our experiments do not speciWcally address the question of detection limits for the ELISPOT and tetramer assays, we could detect a high variability in the sensitivity of protocols used by the diVerent participants. The majority of labs (y = 90%) is able to detect responses with a frequency above 1 per 1,200 CD8 + T cells in the tetramer assay or responses with a frequency above 1 per 2,859 PBMC in the ELISPOT. Note that some of the centers could reliably detect a response with a frequency of about 1 per 8,000 CD8 + T cells in the tetramer assay and about 1 per 40,000 PBMC in the ELISPOT assay. These low frequencies are in the range of that is commonly reported as the detection limit for internally validated protocols for both technologies [39, 40, own unpublished observations] . Another important task of standardization eVorts should be to decrease the variation of results obtained in a group of several laboratories down to the stable and low values (15-30%) that can be reproducibly found within single labs. In order to quantify the variation of results among laboratories we calculated the coeYcient of variation for all 14 reactivities of the two panel phases. The CVs were determined on the base of centers that were able to detect the respective T cell response and the results are shown in supplementary Tables S1a, b. As expected, the CVs we found in our inter-laboratory testing project were higher than those reported from intra-center analysis [39, 40] .
In the ELISPOT assay, the background spot numbers obtained by the diVerent participants varied greatly, but we were unable to correlate this Wnding to a distinct variable. Since the spontaneous cytokine secretion impacts signiWcantly on the sensitivity of this assay, factors that especially inXuence the non-speciWc spot production, possibly the medium type or serum source, will need to be systematically analyzed in a separate study.
The main conclusions from our study have been drawn on the basis of subgroup analyses. Although the CIMT panel in general (13 centers in this initial action), and consequently the subgroups formed during the analysis were rather small, we could already identify statistically signiWcant diVerences in the ability to detect positive responses. We concluded that the number of counted CD8 + T-cells is the most inXuential crucial factor for the tetramer assay and that the combination of a resting-time and a high number of PBMC leads to increased sensitivity in the ELISPOT assay. This suggests that the impact of the identiWed technical variables on the quality of the assays is high. In order to identify those protocol variables that lead to more subtle diVerences, a larger group of participants would be needed.
In addition to the systematic identiWcation of variables that correlate with sensitivity/insensitivity of various assays, inter-laboratory testing projects also allow the rapid evaluation of individual performance among a group. Interestingly, the Wnding that experienced laboratories did not perform better than laboratories which recently applied these techniques strongly suggests that non-optimal protocols, once established in a lab, can commonly be maintained for several years. Periodic comparison of local protocols with those of other centers is recommended. Even if a new staV member uses an established protocol, it is recommended to have them participate in inter-laboratory testing/teaching exercise. Regular participation in multi-center comparisons could thereby help to optimize and validate participants' performance over time and to maintain sensitive protocols or minimal standards. This is of great importance when material from expensive clinical trials has to be analyzed.
All data from the CMV-serology, from the pre-testing experiments and from the results generated by the participating laboratories in ELISPOT and tetramer staining were taken together for each donor in order to qualitatively validate the presence of CMV-and inXuenza-speciWc T-cells. To estimate the quantity, i.e. the frequency of speciWc T-cells in each donor, we calculated the average of all qualitatively positive results, as well as the standard deviations.
This procedure constitutes only an approximation of the real number of antigen-speciWc cells present in a given sample, and cannot be taken as a method for determining absolute T-cell frequencies. Cell samples that contain pre-deWned numbers of antigen-speciWc T-cells (e.g. spiked T-cell clones), especially tumor-reactive T-cells, are not easily available for use in multi-center comparisons, although such standard samples are urgently needed. We see this as one major bottle-neck for the optimization and standardization of immunomonitoring techniques. Methods to generate such standard samples for broader use will therefore be elucidated with high priority in the near future for the next phases of this international collaboration. Another big challenge will be to deWne accepted rules for the settings of the equipment used in these analyses (Xow cytometer or ELI-SPOT reader) in order to uniformly process and analyze the raw data. Ten from eleven laboratories that performed the ELISPOT assay in the Wrst phase used an ELISPOT reader for spot counting. It is known that spot counts between centers can diVer signiWcantly and this may be explained by the use of diVerent reading machines, diVerent settings for the same type of machine or by the experience of the operator. Within this group, four diVerent commercially available reading systems were used (supplementary Table S2 ). We were not able to identify diVerences between the types of ELISPOT readers. A new ELISPOT panel phase is currently in preparation, that will speciWcally focus on the performances of diVerent ELISPOT readers and try to introduce tools to control inter center variation. In addition, none of the participant reported on the use of live/dead cell discrimination on thawed PBMC samples for the FACSbased experiments. Whether the combination of staining with Ab/HLA-tetramers and vital dyes or with a resting phase is beneWcial for increasing the sensitivity of the tetramer staining assay could be addressed in future testing actions.
Results from a proWciency panel of 36 laboratories from nine diVerent countries in which the ELISPOT assay was validated are now also being reported [41] . This initiative, conducted under the aegis of the Cancer Vaccine Consortium (CVC), was mainly designed to oVer an external validation to the participating laboratories but the in depth analysis of the obtained data sets lead to similar Wndings and recommendations as the CIMT monitoring panel. It conWrmed that a resting phase of cells prior to addition to the ELISPOT plates is advantageous and should therefore be generally recommended. Furthermore, a long year experience in a technology did not guarantee for a sensitive test and failure to detect speciWc T cell responses concentrated on the weak responses. The fact that two independent initiatives come to similar Wndings is surely notable and shows the necessity to carry on running proWciency panels.
Last but not least, we would like to stress that even the best guidelines and protocols alone cannot guarantee good performance. Monitoring of antigen-speciWc T-cell responses requires skills as well as experience. Participation in immunomonitoring panels cannot compensate for the need to constantly educate and train staV and to develop speciWc expertise for covering individual needs. Nevertheless, we strongly believe that by organizing further two-step interlaboratory testing projects, the CIMT monitoring panel will be able to improve the sensitivity of the assays used for immunomonitoring as well as to actively participate in the harmonization of these assays, which is required to enable the comparison of immunotherapeutic trials performed in diVerent centers.
